Pod Insights Masters of Scale How Reid Hoffman’s new company will create cancer cures About this episode Reid Hoffman shares the inside story this week of his bold new venture to disrupt cancer drug development: Manas AI. He chats with Jeff Berman to reflect on why he co-founded the company, the lessons he’s using to scale it, and what advice he has for fellow entrepreneurs and investors about how to make the most of AI in any industry.
Rapid Response podcast conversation on Superagency: https://mastersofscale.com/reid-hoffman-on-ai-superagency/
Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Transcript 6,411 words · 11 speakers
0:01 Speaker 00 We've all spent money on something that seemed incredible, but didn't live up to the hype. A kitchen gadget, a car. When it doesn't deliver, the disappointment is real. Marketers suffer from this too. Chasing metrics that look great, but don't translate into revenue. LinkedIn calls that bull spend. Invest in what matters and reach the right buyers with LinkedIn Ads. You can target by company, industry, job title, and more. LinkedIn Ads also generates the highest ROAS of all major ad networks. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/scale. That's LinkedIn.com/scale. Terms and conditions apply.
0:48 Speaker 00 The very best founders I know are brilliant at building systems. They connect teams, they remove bottlenecks, and they eliminate single points of failure. And yet, when it comes to their own wealth, most are running a disconnected stack. A tax accountant here and a state attorney there, a wealth manager who doesn't talk to either one of them. Creative Planning was built to fix exactly that. One integrated team of tax professionals, state planners, investment specialists, all coordinated by a dedicated wealth manager who sees your full financial picture and keeps every piece working together. Proactive tax efficiency, estate strategy, investments, all under one roof.
1:32 Speaker 00 Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale.
1:41 Speaker 01 AI is full of possibilities. Enterprises run on realities. That's why Pega combines the world's most powerful AI with the governance, transparency, and control enterprises demand. So you can move faster, adapt faster, and scale AI with confidence. All the power of AI, none of the uncertainty. Learn more at Pega.com/AI.
2:09 Speaker 00 This week on Masters of Scale, Reid Hoffman is here to tell us all about the new company he's launched, Manus AI. To say that Reid has formed brilliant team would be a big understatement. To say that they have ambitious goals would be an even bigger one. Reid has put some of the world's most powerful AI tools in the hands of some of the world's best researchers. The mission? To discover new ways to treat disease and to actually, finally, cure cancer.
2:39 Speaker 02 You've got to have incredible talent at every position. It's like this huge push. There are fires burning when you're going home. Can you believe it?
2:46 Speaker 03 Such an idiot. And then you go back to, this is totally going to be amazing.
2:51 Speaker 04 There are so many easy wins. I have no idea what to do.
2:54 Speaker 03 Sorry, we made a mistake.
2:55 Speaker 04 But you have to time it right.
2:57 Speaker 03 Oops.
2:58 Speaker 04 Working out of a three-bedroom apartment.
2:59 Speaker 05 Stuff that just seems absolutely nutballs. 10 years later, we're like, well, that's just how you do it. We haven't made it. Just how you do it.
3:09 Speaker 00 This is Masters of Scale. I'm Jeff Berman, your host. We're checking in with our very own Reid Hoffman this week, whose 2025 has had a very busy start. In addition to publishing a book, Super Agency, in January, he also co-founded a new company. We thought it would be interesting to hear how Reid tackles starting and blitzscaling a brand-new business from scratch. Reid, welcome back to your show.
3:39 Speaker 02 It's great to be here. And, you know, hey, I think at this point, it's appropriately our show, but yes.
3:46 Speaker 00 I'm, as always, thrilled to get to see you and chat with you, and I'm especially so today because we're going to talk about Manus. And would you just tell us what Manus is, what you're setting out to do?
3:57 Speaker 02 So Manus is kind of a new AI-driven drug discovery company, targeting primarily cancer, that says, we have this AI revolution, which creates these enormously new, better cognitive artifacts. And how can we deploy that in various ways to get drug discovery superpowered?
4:20 Speaker 02 And it came about because I'd kind of gone to my partner's Greylock and I'd said, "Look, I think there's going to be a lot of great investments in agents and productivity tools and work automation and a bunch of those things and we should do all those and I'll help. But I'm really interested in this area of there's a bunch of things that this AI technology could really make a huge difference, you know, in the world, for societies and industries." And currently, most of the AI people are all looking at all the software stuff. And I said, "Well, would you have mine?" He said, "Well, drug discovery." And so I went out and started talking to some of my smart friends, one of whom is Siddhartha Mukherjee.
4:57 Speaker 00 He's a very smart friend.
4:59 Speaker 02 Yes, very smart friend. Professor at Columbia, world-renowned oncology researcher, Pulitzer Prize-winning author of multiple books, including The Emperor of All Maladies, you know, just massively talented guy. And I'm talking to him for a while and he said, "Well, you know, I'm an entrepreneur too." And I was like, "No, I didn't know that." He's like, "Well, no, I've actually brought cancer drugs to market. I'm not just casual about this. I've actually know this stuff." And I said, "Oh, that's interesting." And he said, "And this sounds like this could be [bleep] amazing. Let's talk about it." That's how kind of Manus came about and that's what Manus is.
5:33 Speaker 00 You've invested in, I'm sure dozens, I'm guessing hundreds of companies at this point. It's very rare that you choose to be a co-founder, but you chose to be a co-founder here. What's your filter for deciding when to invest and when to co-found and why be a co-founder here?
5:49 Speaker 02 Well, co-founder in this case is not quite the same thing I met when co-founding LinkedIn, which is Saturday morning, I'm in the office. And so it's, it is still co-founder because it's like at least a day a week. But it's when you have a CEO co-founder who is exactly the right kind of person that I know how to add in, in the way that a co-founder adds in versus, for example, a board member, which is different in these cases. I mean, there's an overlap with the board member and obviously, obviously a board member of Manus as well. And Sid and I spent a couple of months basically whiteboarding out the entire drug discovery process from, you know, the "I have an idea" to a drug entering
6:34 Speaker 02 the market and slicing it as thinly as possible and understanding what each of these stages were. And then what we do is we talk about my current understanding of what AI is, what I would predict AI is going to go to in one to three years naturally, what things might be possible with AI that are not part of the natural trajectory that like we could create or stimulate uniquely as a business. And then kind of going through all those. And that's when Sid was like, look, I think you need to co-found this with me. Because in a sense, I'm the person who's responsible for making sure the various kinds of parts of the AI talent. I mean, he's enormously talented guy, learns things lightning fast and has a very deep understanding.
7:17 Speaker 02 He also has that sideways understanding you want entrepreneurs to have, which is, well, why is it this way? And why couldn't it be some way that's a lot better? Which is kind of one of the things that's fundamental to the entrepreneurial impulse. And it was like, okay, great, because it's, A, it's a huge mission. Cancer is a huge killer. It kills children. It kills healthy adults. It kills old people. It kills people in every culture, every society. So it's like, okay, this is a huge thing. And by the way, there's not just one cancer. There's lots of cancers. That's one of the reasons why it's a real problem. It's like, hey, we figured out this cancer. And so it's like, okay, what is the way that we make a dent on this whole, whole problem? And that really matters. And then also, of course, when you transform an industry.
7:59 Speaker 02 And so, you know, part of this is to say that there's obviously a lot of things that the drug pharma industry is really, really good at. It's been doing this for a long time. It's added a whole bunch of society, but it's very classic industry. It's very rooted in the way they've been doing things for the last X decades. And it's like, okay, so you could create a new one like the other giants because you're bringing in new things. Those combination of Sid, an important target, possibly transforming an industry, an elevation of humanity.
8:34 Speaker 02 That all gets me into co-founding.
8:36 Speaker 00 I mean, that deep mission alignment is so clear here. And I'm curious, as you and Sid were on that whiteboard and you are slicing into the step by step by step by step by step, what did you see that got you fired up about how AI is such a difference maker?
8:54 Speaker 02 When Sid and I went through the whole area, we abandoned any interest in AI things. There wasn't a minimum of 10x. And frequently it was like, okay, no, no, it's much greater than 10x if we can make this work. And then focus on those areas. And then we didn't go, we're going to invent all the technology. We said, okay, which technology should we be building? And then which technology can we use? And that's part of what led us into partnering with Microsoft, because both Sid and I, from two different angles, had some understanding of where Microsoft was had been working on some pretty unique technology that hadn't really been and hasn't really been fully advanced to the market. And hey, this could be a good way for Microsoft to get in this as well, not just as a sure, but you know,
9:36 Speaker 02 some of the stuff that the excellent Microsoft research has been doing as baseline. And let's do some areas where we're building, do some areas where we're deploying. Some of the deployment is open source, some of the deployment is Microsoft stuff, some of the deployment is other things that we've learned and discovered as you're kind of along the way. And then the way you put them all together, including the things you're building, as the kind of angle for having the technology strategy and doing that, that's much more my network than Sid's network. Sid's networks is the, you know, world-class scientists and and other folks in mine is the tech people.
10:11 Speaker 00 I want to drill down into this for a minute, because I think this is a really important part of this next phase of how people are solving problems with AI as a, to borrow Microsoft's term, a co-pilot. We're all by now familiar with ChatGPT, or Pi, or other AI companions effectively, helping us figure out what's for dinner. And most of us by now are familiar with something like Sierra for customer service, or Harvey for legal tech, for legal AI. The blend of where you are using someone else's AI, where you are customizing for yourself, where you're building for yourself. Help us understand how you make those decisions and how business leaders should be approaching these problems as they're making these decisions for their own companies.
10:56 Speaker 02 Great question and a very good one for matches scale too, because it's generalizing out of the problems we're solving to problems that a lot of people are solving. So for us, it kind of comes down to a couple of things. So one is anticipating where there's going to be a really good continuing workflow where some other entity could be an open source thing, could be a, and it could be us contributing to an open source thing too. But an open source thing could be a proprietary model. That we say, well, actually, in fact, that investment thesis of going forward on that, we will benefit from that at at least, call it 70%, 80% plus of that ongoing technological development is going to benefit us and can be in the slot. And if we were to start doing it ourselves, we wouldn't get something that was at least
11:41 Speaker 02 10x better than what's happening. Then we should use the existing one. So that's, you know, one kind of decision about when you do the open source thing or when you deploy someone else's commercial library or other direction. Another one might be, well, we're going to use the commercial library right now or the open source library right now, but that's a time-saving measure of us getting to market. We think we're ultimately going to build something here, but we don't need to build something here in order to get to market and get it going. So we'll deploy it for now. And by the way, you might have a much cruder or not perfect. And then there's a kind of the question of, okay, which things will be ongoing where
12:23 Speaker 02 we're learning our ground truths, where we're getting the data, where this is, gives us a ongoing substantive competitive advantage about like things that we have as kind of unique assets, other than just the prospective molecules that we're creating that could be cures for various kinds of cancer. Then on that list, which of those things do we start right now? Which are the things to do later? That kind of gets to a high priority. Now, part of, of course, what we have at Manus that is advantageous and I recommend to try to do to all of our, you know, listeners is that I have a very good sense and a very good network of both where AI is now, where new techniques are coming out, where the current trajectory is going.
13:08 Speaker 02 And those kinds of things play in that kind of strategic decisioning. And then that's one of the things that you need to do when you're making these decisions yourself. Now, what happens with everyone in technology, especially in software, is it gets very not invented here. So go, well, I should just control my own destiny. I should just do it. The problem is with tech, software tech, is that it's not build once and forget it. Software tech has to be constantly rebuilt, reinvented, rebuilt, reinvented. And if you're not in that theme, your thing will outmode very quickly. It's one of the reasons why most governments around the world have really broken RFP solutions for technology because they go, oh, I will specify the 150 requirements.
13:49 Speaker 02 And then when whoever provider, usually pretty incompetent people, prime contractors, et cetera, when it comes to software, deliver something to you, not only is it not very good at the beginning, but it starts aging exceptionally fastly from the beginning because it's not part of this stream. So one of the things you, you know, we think about at Manas, but also one of the things our audience should be thinking about is to say, okay, do I really need something specific for me or can I be benefiting on the weekly, monthly, yearly reinvestment that company X or project group Y or something else is doing on this? Because then I don't have to be using some of my relatively few resources for cycling in the future. And that's part of how we look through it.
14:34 Speaker 02 That's part of the reason why some of the stuff we said, hey, we're just going to do that the standard way an AI person does, or hey, we're going to do that the same way a drug researcher does or a drug developer does. We're just going to do that the same way. Because doing that the same way gives us a, the ability to be deploying that, not having risk, not having to invest in it. And, you know, you have to be very choiceful, even as large companies, about which things you're, you're investing in for proprietary reasons.
15:03 Speaker 00 More with Reed on how he's using a lifetime of scale lessons to supercharge his new company in just a minute.
15:25 Speaker 00 We all know the disappointment that comes when a grand gesture falls flat, something that seemed impressive in the moment, but didn't deliver the results you expected. Marketing budgets too often fall into that trap, aiming for big impressions, big reach, but without the revenue to back it. LinkedIn has a name for it, bull spend. LinkedIn ads generate the highest ROAS of all major ad networks. They target by company, industry, job title, and more. Spend $250 on your first campaign on LinkedIn ads and get a $250 credit for the next one. Just go to LinkedIn.com/Scale. That's LinkedIn.com/Scale. Terms and conditions apply.
16:08 Speaker 00 When you've built substantial wealth through your business, it's often tied up in a single equity position. The upside is real, but so is the risk, and knowing when to act isn't always obvious. Creative Planning works with business owners to build a strategy around concentrated equity, when to diversify, how to manage tax risk, and how to protect what you've spent years building. Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale. Stripe Treasury is your new financial operating system built for what's next. With Stripe Treasury, the place your business accepts payments is also where you can store balances, move funds, and pay vendors worldwide. If you're
16:52 Speaker 00 building for global scale, get a business bank account that lets your money move instantly, whenever and wherever you need it. Learn more at Stripe.com/Treasury. Stripe is not a bank. Banking services provided by Fifth Third Bank, National Association Member FDIC.
17:13 Speaker 00 Welcome back to Masters of Scale. You can find this conversation and more on our YouTube channel. One of the things that struck me, Reid, when you first told me about Manus was this beautifully complimentary meeting of you and Sid and your skills and your relationships and your access, your knowledge. You were also entering a category where there are a number of companies already using AI to do drug discovery and to solve critical medical problems. And you all raised a lot less money than most of these companies have raised. How are you able to do that? What's the competitive advantage that you have? And I appreciate it's mission driven, but still you're entering a market where there are already folks who are steps ahead here.
17:59 Speaker 02 Well, we don't think there's steps ahead.
18:01 Speaker 00 Okay.
18:01 Speaker 02 That would be a different question.
18:03 Speaker 00 Fair.
18:03 Speaker 02 Part of it is, so some of these projects tend to be to raise a whole bunch of money and throw the money at either the kind of classic AI stuff or the classic drug discovery stuff.
18:14 Speaker 00 Yep.
18:15 Speaker 02 So part of the thing that we're doing with the financing of Manus is to start in a classic Silicon Valley way that I find to be most successful and how it drives, which is start with a really focused project, a series A investment, and move to you're going to raise more money from your series B and then from your series E. But it's as you accomplish things, you go. One of the things that is frequently challenging and frequently counter predictive for successful projects, in my experience, has been when you raise way too much capital initially. And that then says, well, it's because we're going to try everything and go really bold and do the whole thing from the start. And that actually makes you, even
18:59 Speaker 02 with a lot more capital, much less likely to be successful. So we will need to raise more money. We will need to raise it for like clinical trials and much of other things. We'll really need to raise a series B for some of the technology, but we will do it. Based on having achieved some interesting outcomes.
19:16 Speaker 00 Yeah, it's one of those interesting parallels between art and startups where constraints actually produce better results often because it requires focus and discipline and choice making. Reed, you're entering a space with Manus that is extremely highly regulated. In the case of drug discovery narrowly and healthcare more broadly, do you see regulation as a constraint? Is this an area of concern? Can you work within the existing world? How does that factor into your analysis here?
19:45 Speaker 02 Well, one of the reasons why I very rarely invest in regulated businesses and would be normally very cautious about co-founding them is that regulation always massively slows down innovation. And regulators like to say, well, in certain cases, it accelerates, which is true. And they like to say, well, but if you do it really smart, it doesn't really. And that actually is no, it isn't because in the natural thing for regulatory agencies to say, I get penalized every time an error happens and I get no upside for things working more efficiently or working more on target or anything else. So I just throw in every possible thing that could be answering a negative. And that's how it works over time,
20:28 Speaker 02 whether it's in the FDA, whether it works in the SEC, whether it works in the banking industry, et cetera. Now, that's all part of the reason why I tend to have this maxim to say, look, you should do regulation when bad regulation is better than no regulation, whether it's an industry, whether it's a specific kind of thing. But you shouldn't delude yourself that you're super smart and a technocrat and that you know how to do this regulation in a way that's so great for the industry that you're going to detail this all out. And it's one of the reasons why, for example, the Europeans have a super large problem with regulation, not just within technology, but also everything that goes
21:09 Speaker 02 to labor and a bunch of other things because they go, no, no, no, we're gonna, we're gonna have it as a multi-page detailed thing. Like, this is not at all saying society is better off without regulation. It's not all saying that parts of the FDA are absolutely critical in anything from food and drugs and that there are things to do. It's just that you need to have a certain epistemic humility and kind of going, hey, we should be very focused. Versus trying to be, we are the genius technocrats. And so that's the reason I generally stay away from regulation. And I only get into the areas where there's regulation when I think, hey, this could be so great. This could be like industry transformer. This could be something that changes many thousands of human lives.
21:51 Speaker 02 And you could see its impact on a society basis of helping elevate society. Then, okay, regulation is a huge risk, like other risks. But that huge risk plays out against that. And that's part of the case in Manus.
22:04 Speaker 00 Right, right. Good regulation is really hard, but it's not an oxymoron.
22:08 Speaker 02 Yes.
22:09 Speaker 00 How fast can Manus go? Curing cancer has been a moonshot concept since we had a concept of a moonshot. How quickly can this happen?
22:18 Speaker 02 Well, I mean, we're early days. Obviously, we did this because we think we can accelerate greatly. We think we can get a lot more targets into the early process than the standard process would have. We think we have ways of evaluating those targets and molecules at a much faster rate than tribunally happens. We think we can be getting into clinical ground truth things at a speed that is on a larger number and much faster. How fast it is, is still TBD. And I think this is one of the things where Sid said, hey, welcome to a regulated industry. Don't quote numbers when you're talking to outsiders. Right? So here I am, following Sid's sage advice and not quoting any numbers.
23:01 Speaker 00 Most of the time when we're having conversations on Masters of Scale, it's about a company that has already scaled. We're having this conversation because you are the OG master of scale. And this is as important as anything that, you know, we could be talking about in terms of the effect on humanity. When we come back a year from now and have a follow-up conversation, what are the markers that will determine whether you feel like Manus is on the right track?
23:27 Speaker 02 We already have some of those markers internally. We've already had some prospective molecules. We've already had some of our technology development. Show things that we think help build secrets that we think no one else knows. So we've already on track on some of that. But I think what we would be saying to the world, oh, we're on track, will probably be like a couple of the pieces of technology saying, hey, these are delivering these things. We might be saying, we have a set of interesting molecules for triple negative breast cancer, other kinds of things we're looking at.
24:03 Speaker 02 And our process has, in fact, gotten us there much, much faster than the traditional drug pharma startup company. That would be some anticipated positive signs.
24:16 Speaker 00 You're obviously using AI to assist in the discovery process and the testing process, et cetera. I would be stunned if you're also not using AI in the day to day operations of the company. What's different about how you and Sid and the team are building the company with AI that is applicable to other companies and other categories from the other companies that you founded or have been a very active investor in?
24:44 Speaker 02 Well, this will obviously scale as we get to it. I mean, right now, we're in kind of raw tech development. So it's tech development and also kind of scientific development. So I would say it's today is probably a little bit more like some other companies, which is it's a research assistant for various kinds of things we're looking at. It's a communication and productivity assistant for generating flow of information decisioning between us. And it's a coding assistant for building certain kinds of code. If you're not in those basic things as a company right now, you're well behind the AI curve and therefore well behind the curve. So all of those things, I think, are things that every company should be doing.
25:29 Speaker 02 And now there may not be a science research assistant in your particular company, but there should be research assistants of some sort. Global supply chains or competitive analyses on products or, you know, whatever that thing may be. And so those things, I think, Our things are not new and unique things. Now, obviously, as you get to questions around, like, say, for example, hey, we have got a drug, and part of the issue is really maintaining complex compliance to the drug, then you could see how AI might actually help with complex compliance to a drug. And there may be some things that kind of get to specific things that are still significantly in the future.
26:10 Speaker 00 Reed, before we wrap, I want to ask you a broader question about what's happening in the world of artificial intelligence. In your book, Super Agency, you talk about the doomers, the gloomers, the zoomers, and the bloomers, in terms of the categories of how dystopian and utopian people are in their vision of AI. When you lean into the bloomer side, into the more optimistic vision of what AI can be, what are you seeing today that we may not know about that has you more optimistic, more excited, more leaning into the AI utopian vision of the future?
26:48 Speaker 02 I'll use an example of, I was hanging out with Atul Gawande. We were talking about his new book that he's working on. And I was like, well, have you used deep research? He's like, no. I was like, okay, let's go. We went to my account in ChatGPT, and we did the deep research prompt on surgeons applying anesthesiology and improving their practice. And it was a really interesting nuance. It's one of the reasons I'm going into the depth of it, because it produced exactly what he wanted, which was 10 quotations from different surgeons. And he's like, he looks at this and says, oh, my God, this is gold. And he sent it off to his research assistant. His research assistant came back and said, well, one problem, nine of the 10 quotes are incorrect.
27:31 Speaker 02 And you go, oh, hallucination, terrible, terrible thing, like, basically not working. But then with the research assistant, what she did was she went and looked at the areas it was pointing to and said, oh, my God, this saved me tens of hours of finding the right treasure troves that are the precise things that will be very helpful to this book. And so even in this kind of hallucination case, because of the research, it was actually still an accelerant. It just is an accelerant, in a way, that kind of proves the point from my earlier book, impromptu, and also part of what I'm trying to say in Super Agency, which is human amplification. With the research assistant, helped make her massively productive very, very quickly.
28:14 Speaker 02 And of course, you should cross check it. You're trying to produce something. I do the same thing when I'm producing my own books, super agency, impromptu, et cetera. I of course, cross check things. I don't say what the GPT four output was. I just cut and paste it in because I am testifying to these words being accurate as a way of doing it. Anyway, so, so even in the hallucinations are improving a lot and doing stuff, but even the hallucinations are interesting, even in potentially importance of high truth fact checking environments. AI is improving every month and it's, it's part of the reason why we tell people, go try it, go play with it because it's not like, oh, I'll wait until it stabilizes. It's not going to stabilize
28:58 Speaker 02 soon and it's already amazing in some regards. So go start leaning into it. Start seeking super agency.
29:05 Speaker 00 Reed, as one of the great investors of really American history, certainly modern American history, and as someone who's deep, deep, deep in AI, for the investors in our audience, probably 90 something percent of their pitches that they're doing right now have AI something. How do you separate the wheat from the chaff here? If you're an investor, how do you know what's, what's real, what's meaningful and what someone has just slapped AI on to be of the moment?
29:32 Speaker 02 Well, when you get a pitch for an AI juice machine, you know, perhaps pass on that. Although watch, after making this prognosis, there's going to be some amazing AI juice machine that I was like a complete idiot saying this, but it just, it's kind of a particular bit of Silicon Valley history lore that that's a fun gesture. It's almost like saying, you know, 42 or San Andreas High School football rules, you know, it's kind of like in the little gestures. Now, being said, there's simple mistakes and complex mistakes. Simple mistakes are that is actually not in fact have anything to do with AI. Oh, I'm going to use buzzword bingo. It's AI quantum, you know, fusion. Ah, you know, and like be cognizant of that. The fact that AI is
30:14 Speaker 02 not a panacea for everything right now. It's not a, it's solve every problem. And even when they say it's accelerating a lot and we'll solve it next year, it's unclear on that stuff. So be smart about that. And the number of teams that are really accelerating the raw intelligence of new capabilities AI is not a large number of N. So be careful about that. Those are all the kind of simple things. Now, the more complex things is And of course, part of the reason why we're in a cognitive industrial revolution here is that adding intelligence to everything, whether it's your PC or your phone, but also your speaker and your lights and your car and like everything is going to be revolutionary. Certainly, human lived experience. And so there are going to be a bunch of new products
30:58 Speaker 02 and services. But a new product and service does not an equity make. And so like, for example, among other things is what will rapidly happen as a whole bunch of these AI models and capabilities, I wouldn't say is a commodity, but is broadly available to many players. So that you say, hey, I can build an AI thing that can be a good tutor. By the way, I can do that today. I literally to put in a little meta prompt into something like, you know, GPT four, Pi or others. And I put it in and say, don't give the answer, work the person towards the answer. And then I've got a mini tutor right now, not having done anything. So they say, well, AI can great that. And I said, well, I'm going to work harder and I'm going to make it better. It's like, okay, that's not nothing. But
31:43 Speaker 02 you're looking for the kinds of structural advantages that you would typically have in a business. It's a systems integration into an organization, you know, a school, a business, it's a network effect. It's some set of things that you go, no, no, this is a product or service that's going to go the distance and compound in value and therefore create equity value. And that's the kind of thing to think about. And one of the things I think people mistake in this revolution right now is that they go, just because it's AI and just because it's moving first, that makes a great equity. And it's like, well, look, that's better than no idea. Right. But if you're really investing intelligently and professionally, you should have incremental and better ideas than that, not just that
32:26 Speaker 02 idea, other ideas as well. And I think that's part of how to think about AI and investing.
32:31 Speaker 00 Reid, I'm super grateful for you joining us to talk about Manus today. I'm very excited to follow up as the Manus journey evolves. Thank you for attacking this problem that has affected probably the family of everyone who's in our audience and can't wait to talk about this again soon.
32:49 Speaker 02 Me too. And Jeff, always a pleasure.
32:53 Speaker 00 Thanks to Reid for sitting down to talk about his exciting new company this week. I know we all hope the scale lessons he's learned over his career can help make Manus AI's drug discovery research a monumental success. It has the potential not just to change lives, but to save them. To hear more about his new book, Super Agency, make sure to check out the conversation he had with our own Bob Safian. We'll put a link in the show notes. I'm Jeff Berman. Thank you for listening.
33:24 Speaker 00 Every business hits the same wall the moment your business outgrows the systems that got you here. Spreadsheets everywhere, five different logins, data scattered across entities that don't even talk to each other. If your finance team spends more time finding data than using it, that's when you need the Intuit ERP. Intuit Enterprise Suite is the AI-native ERP solution that's powerful, painless, and proven. Built for businesses scaling fast without the complexity that usually comes with it. From the makers of QuickBooks, learn more at intuit.com/erp.
34:05 Speaker 00 Before we get to the rest of our conversation today, I want to spend a moment sharing with you about Masters of Scale Summit, which returns to San Francisco this October 20th to 22nd. So many of us feel overwhelmed right now. It feels like so much of the world is careening and we don't have power, we don't have agency. That's the thing about the Masters of Scale Summit. It's really designed to remind us that we do have agency. Agency to lead, agency to design, to build the relationships and the partnerships that empower us and to make the change that we want to see. We program a stage, we curate an audience, we set a schedule that builds in time for these relationships to be made and to grow so that
34:48 Speaker 00 by the time you leave Summit, you are fired out of a cannon, ready to run through walls to do better in the world with the agency that you actually have. I hope to see you there. Visit mastersofscale.com/summit.
35:08 Speaker 06 Hey listeners, Bob here. If you listen to Rapid Response on Masters of Scale, you may be missing half the show because every Friday, we release a second Rapid Response exclusively in the Rapid Response feed. The guests and topics are just as compelling and timely, from Ford CEO to NASA's administrator to the lessons from the devil wears Prada. It takes about 10 seconds to find. Just search Rapid Response wherever you listen to podcasts and hit follow to make sure you never miss an episode. I hope to see you there.
35:47 Speaker 00 Masters of Scale is a Wait What original. Our executive producer is Eve Trow. Our senior producer is Tricia Bobita. The production team includes Tucker Legursky, Masha Makotunina, and Brandon Klein. Our senior talent executive is Stephanie Stern. Mixing and mastering by Aaron Bassinelli and Brian Pugh. Original music by Ryan Holiday. Our head of podcasts is Lital Malad. Visit mastersofscale.com to find the transcript for this episode and to subscribe to our newsletter.
36:28 Speaker 07 Humans will never be more intelligent than AI.
36:31 Speaker 08 There's going to be two types of companies. Those who are great at AI and those that went out of business because they weren't.
36:36 Speaker 09 How do we build a future that is human centered?
36:41 Speaker 10 I'm Rana Elkhayubi, and on my podcast, Pioneers of AI, we answer that question and so many more. As an AI scientist, entrepreneur, and investor, I know what it takes to build AI that works for everyone. Every week, I sit down with the pioneers shaping our future, and we take you behind the scenes of the AI that's transforming our lives.
37:06 Speaker 10 Find Pioneers of AI wherever you tune in.
Previous From data breach scandal to AI darling, with Snowflake’s CEO Sridhar Ramaswamy Next When powerful law firms don’t defend themselves against Trump, with ex-Skadden associate Rachel Cohen Page updated October 16, 2026 · transcript and summary are machine-generated